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Abstract: Antibody-based delivery of bioactive molecules represents a promising strategy for the im-
provement of cancer immunotherapy. Here, we describe the generation and characterization of R6N,
a novel fully human antibody specific to the alternatively spliced domain D of Tenascin C, which is
highly expressed in the stroma of primary tumors and metastasis. The R6N antibody recognized its
cognate tumor-associated antigen with identical specificity in mouse and human specimens. Moreover,
the antibody was able to selectively localize to solid tumors in vivo as evidenced by immunofluorescence-
based biodistribution analysis. Encouraged by these results, we developed a novel fusion protein (termed
mIL12-R6N) consisting of the murine interleukin 12 fused to the R6N antibody in homodimeric tan-
dem single-chain variable fragment arrangement. mIL12-R6N exhibited potent antitumor activity in
immunodeficient mice bearing SKRC52 renal cell carcinoma, as well as in immunocompetent mice bear-
ing SMA-497 glioma. The experiments presented in this work provide a rationale for possible future
applications for the R6N antibody for the treatment of cancer patients.
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